Marijuana Rescheduling and 280E: What Has Actually Happened and What It Means for Cannabis Companies

This guide is for investors, cannabis and hemp business owners, and anyone trying to separate rescheduling headlines from what the law now says. It sets out, as of November 19, 2026, which federal actions are final, which are still proposed or in court, how Internal Revenue Code Section 280E works, and how to read a cannabis company’s tax disclosures in light of all this. Everything here comes from the Federal Register, the DEA, Treasury, the IRS, Congress.gov and company filings.
This article is for education only and is not investment, legal, or tax advice. Investing involves risk, including loss of principal.
- Final: A Justice Department order effective April 28, 2026 placed FDA-approved marijuana drug products and marijuana held under a state medical marijuana license in Schedule III.
- Not final: Moving all marijuana, including adult-use, to Schedule III is still a proposed rule. The DEA hearing ended in July 2026, and as of November 19, 2026, no recommended decision or final rule had been published.
- In court: Petitions challenging the April order are pending in the U.S. Court of Appeals for the D.C. Circuit.
- 280E: The order says medical licensees are no longer subject to 280E. Treasury and the IRS have announced planned guidance, but we found no published notice or regulation as of this date. Adult-use activity remains subject to 280E.
- Banking: The SAFE Banking Act of 2026 has been introduced in both chambers but has not passed either.
Table of Contents
The timeline in brief
| Date | Event | Status |
|---|---|---|
| May 21, 2024 | Justice Department proposes moving marijuana from Schedule I to Schedule III | Proposed rule |
| Aug. 29, 2024 | DEA notice of hearing on the proposal | Later withdrawn |
| Dec. 18, 2025 | Executive Order 14370 directs the Attorney General to finish the rescheduling rulemaking as quickly as federal law allows | In effect (directive only) |
| April 28, 2026 | Final order places FDA-approved marijuana drugs and state-licensed medical marijuana in Schedule III | Final, effective that day |
| April 28, 2026 | DEA withdraws the 2024 hearing notice and issues a new one for the broader proposal | Hearing process restarted |
| June 29 to July 15, 2026 | DEA administrative hearing on moving all marijuana to Schedule III | Held; decision pending |
| May 22, 2026 | Nebraska, Indiana and Louisiana petition the D.C. Circuit to review the April order | Pending |
What the April 2026 final order did
The order, published at 91 FR 22714, used a provision of the Controlled Substances Act that lets the Attorney General schedule a drug as needed to meet U.S. treaty obligations under the 1961 Single Convention on Narcotic Drugs, without the usual findings and hearing. Because it relied on that treaty authority, it was issued as an order effective on publication rather than after notice and comment.
Its main parts:
- Scope. Schedule III now covers marijuana, marijuana extracts and plant-derived delta-9 THC that falls outside the hemp definition, but only when it is in an FDA-approved drug product or is subject to a state license to make, distribute or dispense marijuana for medical purposes.
- Everything else stays in Schedule I. The order says plainly that marijuana in any other form remains Schedule I, with the same criminal and civil exposure as before. That includes adult-use (recreational) sales. Synthetic THC also stays in Schedule I, and hemp is unaffected because it is excluded from the definition of marijuana.
- DEA registration for state medical licensees. The order creates an expedited registration route. A state medical license serves as evidence of state authorization, and DEA must grant registration unless doing so conflicts with the public interest or treaty obligations. Applications filed within 60 days of publication were to be processed within six months, and early applicants could keep operating under their state licenses while DEA reviewed them. A federal registration lapses automatically if the state license is suspended, revoked or expires.
- Treaty mechanics. To meet the Single Convention, DEA nominally buys and resells registered manufacturers’ crops, and imports and exports still need permits.
Executive Order 14370, which prompted this action, is a directive to agencies. It does not itself change any schedule. It told the Attorney General to complete the rescheduling rulemaking “in the most expeditious manner” allowed by federal law, and asked White House staff to work with Congress on the hemp-derived product definition.
What is still pending
The broader rescheduling rule
The May 2024 proposal to move all marijuana to Schedule III remains a proposed rule. On April 28, 2026, DEA withdrew its 2024 hearing notice, ended those proceedings, and published a new notice of hearing. According to an October 14, 2026 order from DEA Chief Administrative Law Judge Derek C. Julius, the merits hearing ran from June 29 through July 15, 2026. After the hearing, some participants asked to add a September 2026 Government Accountability Office report to the record and to reopen the hearing, and the judge stayed the matter while those motions were decided. DEA’s hearing docket page later posted an order admitting the GAO report and allowing briefing on it, while denying the request to reopen the hearing.
The normal next steps are a recommended decision from the judge, exceptions from the parties, and then a final decision by the DEA Administrator, which would be published as a final rule. As of November 19, 2026, the docket page listed no recommended decision, and a search of the Federal Register found no final rule rescheduling marijuana as a whole. Until one is published and takes effect, adult-use marijuana is Schedule I.
Litigation over the April order
The April order is being challenged. Nebraska, Indiana and Louisiana filed a petition for review in the D.C. Circuit on May 22, 2026 (Case No. 26-1130). They argue that the order was improperly issued, conflicts with the CSA and the Single Convention, and is arbitrary and capricious, and they ask the court to vacate it. As of November 19, 2026, we found no court decision vacating the order, so it remains in effect, but a ruling against it could undo part or all of it.
Congress can also change marijuana’s status by statute. The Congressional Research Service noted in October 2026 that Congress could act before or after DEA makes a final decision.
How Section 280E works
Section 280E was added to the tax code in 1982. It says that a business consisting of trafficking in Schedule I or II controlled substances, in violation of federal law or the law of the state where it operates, may not take any deduction or credit. Because it has generally been read to leave cost of goods sold in place (one large operator’s 10-K describes the IRS position as allowing only amounts properly treated as cost of goods sold), the practical effect is to tax a cannabis retailer on something close to gross profit rather than net profit.

Illustrative example (round, hypothetical numbers, federal tax only, using the 21% federal corporate rate):
| Line | Normal business | Same business under 280E |
|---|---|---|
| Revenue | $1,000,000 | $1,000,000 |
| Cost of goods sold | $500,000 | $500,000 |
| Rent, wages, marketing and other expenses | $400,000 (deductible) | $400,000 (not deductible) |
| Pre-tax profit | $100,000 | $100,000 |
| Taxable income | $1,000,000 − $500,000 − $400,000 = $100,000 | $1,000,000 − $500,000 = $500,000 |
| Federal tax at 21% | $21,000 | $105,000 |
| Tax as a share of pre-tax profit | 21% | 105% |
In this example the 280E business owes more federal tax than it earned. That is why effective tax rates above 100% appear in cannabis company filings, and why rescheduling matters so much to their valuations.
Hemp businesses are not subject to 280E when they operate within the federal hemp definition, because hemp is not a controlled substance. Our guide to hemp business banking and insurance covers the other areas where hemp and marijuana are treated differently.
What rescheduling means for 280E
Because 280E applies only to Schedule I and II substances, moving state-licensed medical marijuana to Schedule III takes medical activity outside its text. The April order says this directly: state medical licensees “will no longer be subject” to the 280E disallowance. It also asks the Treasury Secretary to consider retroactive relief for earlier years, and it states that it does not decide anyone’s federal tax liability.
On April 23, 2026, Treasury and the IRS announced that they plan to issue guidance on the order’s tax effects. According to the announcement, the guidance is expected to:
- confirm that rescheduling generally removes 280E as a bar for businesses that no longer traffic in Schedule I or II substances;
- explain that for businesses with several activities, 280E applies only to the Schedule I or II activity, for example by apportioning expenses; and
- include a transition rule treating rescheduling as applying for a business’s full taxable year that includes the order’s effective date, so a calendar-year medical operator would generally look at all of 2026.
The 2026-2027 Priority Guidance Plan released by Treasury and the IRS lists “Guidance under §280E” as a project. As of November 19, 2026, we did not find a published notice, revenue procedure or regulation implementing it. The plan itself sets no deadline. Retroactive relief for years before 2026 has been requested, not granted.
For businesses with both medical and adult-use operations, the adult-use side remains Schedule I trafficking, so 280E still applies to it. How expenses get split between the two sides will depend on the guidance that has not yet been issued.
Banking legislation status
Rescheduling to Schedule III does not by itself make marijuana banking routine. Marijuana remains a controlled substance in every schedule, and FinCEN’s 2014 guidance on marijuana-related businesses still sets out the suspicious activity reporting banks follow, including “marijuana limited,” “marijuana priority” and “marijuana termination” reports. We found no updated FinCEN guidance reflecting the April 2026 order as of November 19, 2026.
In Congress, as of November 19, 2026:
- S. 4942, the SAFE Banking Act of 2026, would protect financial institutions that serve state-sanctioned marijuana businesses and their service providers. It was introduced June 24, 2026 and referred to the Senate Banking Committee. That is its only recorded action.
- H.R. 9471, the SAFE Banking Act of 2026, was introduced in the House on June 25, 2026, referred to the Financial Services, Judiciary and Veterans’ Affairs committees, and referred to a Veterans’ Affairs subcommittee on July 17, 2026.
- The earlier SAFER Banking Act (S. 2860) from the 118th Congress was reported by the Senate Banking Committee in September 2023 but never passed the Senate. It expired at the end of that Congress.
None of these is law. Note that an unrelated House bill, H.R. 8338, is titled the “SAFER Act of 2026.” It deals with state seizure of investment accounts, not cannabis banking, so don’t confuse it with the SAFER Banking Act.
What investors should watch in filings
- Medical versus adult-use revenue. Only the medical share benefits from the April order. A company that reports one blended revenue line makes this harder to judge.
- DEA registration status. Did the company apply within the 60-day window, and has DEA granted registrations? One large operator reported in its September 30, 2026 quarterly filing that it had received DEA registrations for nearly all its dispensaries.
- Tax provision and uncertain tax positions. Many operators built up large liabilities for unpaid 280E tax from earlier years. Rescheduling does not erase those liabilities unless retroactive relief is granted. Our guide to reading cannabis company filings explains how to find them.
- Corporate restructurings. Some companies are separating medical and adult-use operations to qualify for exchange listings. See how marijuana stocks work.
- Legal risk factors. Look for discussion of the D.C. Circuit challenge and the pending DEA proceeding, and of what happens if either goes the other way.
Promoters tend to seize on rescheduling headlines. Our investment red flags guide applies equally to marijuana stocks.
Frequently asked questions
Is marijuana Schedule III now?
Partly. As of November 19, 2026, marijuana in FDA-approved drugs and marijuana held under state medical licenses is Schedule III under the order effective April 28, 2026. All other marijuana, including adult-use, remains Schedule I while the broader proposal is pending.
Did 280E go away for cannabis companies?
Not for everyone. The order says state medical licensees are no longer subject to 280E, and Treasury plans guidance on how that works. Adult-use activity is still Schedule I trafficking, so 280E continues to apply to it.
Will cannabis companies get refunds for past 280E taxes?
That has not been decided. The order asks Treasury to consider retroactive relief, and Treasury described a transition rule for the year that includes the effective date. Neither grants refunds for earlier years.
Could the April order be reversed?
Yes. Petitions asking the D.C. Circuit to vacate it are pending, and Congress or a later administration could act. Until then, the order is in effect.
Has the SAFE or SAFER Banking Act passed?
No. As of November 19, 2026, the SAFE Banking Act of 2026 is at the introduced and committee stage in both the Senate (S. 4942) and the House (H.R. 9471).
Federal cannabis policy is moving quickly. Check the Federal Register, DEA’s rescheduling docket and Congress.gov before relying on any status described here.
Sources
Credit: the facts, figures and rules in this article come from the organizations and authors listed below. All credit for their research and data belongs to them; follow the links to read the originals.
- U.S. Department of Justice / DEA, Final Rule: Rescheduling of FDA-Approved Products Containing Marijuana and State-Licensed Medical Marijuana to Schedule III, 91 FR 22714 (2026)
- DEA, Schedules of Controlled Substances: Rescheduling of Marijuana, Notice of Hearing on Proposed Rulemaking (2026)
- DEA, Rescheduling of Marijuana: Withdrawal of 2024 Notice of Hearing (2026)
- The White House, Executive Order 14370: Increasing Medical Marijuana and Cannabidiol Research, 90 FR 60541 (2025)
- DEA, Proposed Rescheduling of Marijuana: Hearing Docket Orders (2026)
- DEA Office of Administrative Law Judges, Order Granting Leave to File a Reply and Order for Response to Motion to Reopen Hearing, Docket No. 1362 (October 14, 2026)
- State of Nebraska et al. v. U.S. Department of Justice et al., Petition for Review, D.C. Cir. No. 26-1130 (2026)
- U.S. Department of the Treasury, Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling (2026)
- Treasury Department and IRS, 2026-2027 Priority Guidance Plan (2026)
- 26 U.S.C. § 280E, Expenditures in connection with the illegal sale of drugs (Legal Information Institute)
- Congressional Research Service, Delay in Changes to Hemp Definition, LSB11496 (2026)
- FinCEN, FIN-2014-G001: BSA Expectations Regarding Marijuana-Related Businesses (2014)
- Congress.gov, S. 4942, SAFE Banking Act of 2026, All Actions (2026)
- Congress.gov, H.R. 9471, SAFE Banking Act of 2026, All Actions (2026)
- Congress.gov, S. 2860, SAFER Banking Act (118th Congress), All Actions (2023)
- Congress.gov, H.R. 8338, SAFER Act of 2026 (2026)
- Trulieve Cannabis Corp., Form 10-Q for the quarter ended September 30, 2026, SEC EDGAR (2026)
- Trulieve Cannabis Corp., Form 10-K for fiscal year 2025, SEC EDGAR (2026)
Figures last checked: November 19, 2026.
🌱 Finished reading? You earned 5 seeds.
Every article you read to the end earns seeds in Hemp Empire, our free hemp farming tycoon game. Play now →
Some links may be affiliate links. As an Amazon Associate, HempDollars earns from qualifying purchases.


Leave a Reply